<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00594191</url>
  </required_header>
  <id_info>
    <org_study_id>SIMV-HTP2003</org_study_id>
    <secondary_id>AEM 03-0434</secondary_id>
    <nct_id>NCT00594191</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Simvastatin in the Treatment of Portal Hypertension</brief_title>
  <official_title>Phase IV-II Randomized, Multicenter, Placebo-Controlled Double-Blind Clinical Trial Evaluating the Effects of Continuous Simvastatin Administration on Hepatic and Systemic Hemodynamics in Patients With Cirrhosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of continuous simvastatin administration
      on the hepatic venous pressure gradient (HVPG), as a surrogate marker of prognosis, and its
      safety in patients with cirrhosis and portal hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Statins exert beneficial vascular effects independently of cholesterol reduction by improving
      endothelial dysfunction. In cirrhosis sinusoidal endothelial dysfunction further increases
      intrahepatic resistance and portal pressure. Previous studies have shown that statins improve
      hepatic endothelial dysfunction in cirrhosis, suggesting that statins could be an effective
      therapy for portal hypertension (PHT). This randomized controlled trial evaluated the effects
      of continuous simvastatin administration on the hepatic venous pressure gradient (HVPG), as a
      surrogate marker of prognosis, and its safety in patients with cirrhosis and PHT.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in hepatic venous pressure gradient (HVPG)</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in systemic hemodynamics</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver function tests</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Portal Hypertension</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo with the same characteristics of the drug and at the same dose</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 75.

          2. Clinical, analytical, ultrasound or pathological criteria of cirrhosis.

          3. Severe sinusoidal portal hypertension (HVPG &gt;12 mmHg)

          4. Signed informed consent

        Exclusion Criteria:

          1. Pregnancy or lactation

          2. Advanced liver disease defined as one of the following: Prothrombin rate &lt;40%,
             Bilirubin &gt;5 mg/dl, hepatic encephalopathy &gt; grade I or Child-Pugh score &gt;12).

          3. Portal vein thrombosis

          4. Multinodular hepatocellular carcinoma or single hepatocellular carcinoma &gt; 5 cm.

          5. Heart, renal or respiratory failure

          6. Previous portal-systemic shunt

          7. Treatment with organic nitrates

          8. Hypersensitivity to HMG-CoA reductase inhibitors

          9. Previous treatment with HMG-CoA reductase inhibitors

         10. Treatment with calcium channel blockers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaime Bosch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hepatic Hemodynamic Laboratory. Liver Unit. Hospital Clinic.</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Gastroenterología, Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28871</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Servicio de Gastroenterología, Hospital Universitario General Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2008</study_first_posted>
  <last_update_submitted>January 3, 2008</last_update_submitted>
  <last_update_submitted_qc>January 3, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jaime Bosch /Professor of Medicine</name_title>
    <organization>University of Barcelona</organization>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>HMG-CoA reductase inhibitors</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Variceal bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

